Supermoon Capital

Mike Masterson, Managing Partner, leads investment decisions. Masterson co-founded Nevro, a neuromodulation company that went public in 2014, and previously served as a VP at Bay City Capital. The firm's website lists two additional partners — Grayson and Pat — but does not disclose their full names, titles, or decision-making authority.

Supermoon applies a structured thesis that breaks the sleep market into 50 distinct segments. The firm targets companies at the convergence of consumer, healthcare, and biotechnology, specifically those that align with its research themes — such as the "medicalization of the consumer" and the "unconscious frontier." It does not invest indiscriminately across the sleep economy.

Supermoon is structured as an asset manager — specifically a private equity firm executing a venture capital strategy. It is not a single-family office. It markets its strategy to scientists, technologists, and institutional partners through its research and content platform.

Supermoon relies heavily on its proprietary research. The firm publishes detailed market maps and original analysis to attract founders building in sleep and circadian science. This content-led approach replaces a traditional broker-driven or GP-referral pipeline, functioning as a direct inbound channel from the scientific and technology communities.

Supermoon invests from seed through early stage. Its public portfolio spans companies that were backed at formation — such as Arcascope — and those that have reached later venture rounds and FDA clearance, like Big Health. The firm typically takes board observer or director roles.

Supermoon makes direct equity investments into operating companies. There is no public evidence that it allocates to external funds or operates a fund-of-funds program. The firm's observer and director board roles confirm a direct, hands-on investment approach.

Supermoon's research explicitly explores the collision zone between consumer wellness and regulated medical claims — what the firm calls the "medicalization of the consumer." It invests across FDA-cleared devices, digital therapeutics requiring regulatory oversight, and consumer products making softer wellness claims, suggesting a portfolio intentionally diversified across regulatory risk levels.